Adrienne Hollander, MD
Rheumatology · Voorhees, NJNPI 1417994633
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,948 of the $213,730 with a category attached, or 65.9%. 18 manufacturers reported payments, led by Amgen at 30.5% of the total. Reporting peaked in 2019 at $72,971 and has fallen 51.9% since, to $35,126 in 2025. Among rheumatology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $531.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65K
- United Rheumatology$58K
- AbbVie$42K
- Janssen Scientific Affairs, LLC$21K
- Johnson & Johnson$20K
- Genentech USA, Inc.$7K
- plus $1K from 12 others
Across 166 payments — averaging $1375.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$110K
- AbbVie$91K
- Amgen$22K
- Pfizer$6K
What the payments were for
- Consulting fees$57,50027%
- Speaking & faculty fees$140,94866%
- Travel & lodging$6,3893%
- Food & beverage$8,4814%
- Education$4120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 104 | $65,170 |
| United Rheumatology | 8 | $57,500 |
| AbbVie | 145 | $42,486 |
| Janssen Scientific Affairs, LLC | 21 | $20,907 |
| Johnson & Johnson(3 entities) | 59 | $19,866 |
| Genentech USA, Inc. | 8 | $6,736 |
| UCB, Inc. | 7 | $234 |
| E.r. Squibb & Sons, L.L.C. | 18 | $183 |
| Novartis | 9 | $169 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| GSK | 6 | $96 |
| AstraZeneca(2 entities) | 5 | $78 |
| Pharming Healthcare, Inc. | 2 | $64 |
| Organon | 2 | $37 |
| Pfizer | 4 | $31 |
| Lilly USA, LLC | 1 | $20 |
| CSL Behring | 1 | $14 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$213,730 in reported general payments places this provider in the 95th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 68 | $476,263 |
| Xeljanz XrTofacitinib Citrate | 28 | $187,025 |
| Enbrel SureclickEtanercept | 25 | $184,226 |
| Taltz AutoinjectorIxekizumab | 12 | $106,624 |
| Teriparatide | 33 | $82,925 |
| SimponiGolimumab | 13 | $74,917 |
| ForteoTeriparatide | 13 | $54,207 |
| MethotrexateMethotrexate Sodium | 475 | $13,737 |
| Hydroxychloroquine Sulfate | 226 | $11,402 |
| Risedronate Sodium | 27 | $3,317 |
| Alendronate Sodium | 327 | $2,884 |
| Leflunomide | 49 | $2,431 |
| Sulfasalazine | 65 | $2,274 |
| Raloxifene Hcl | 25 | $2,065 |
| Duloxetine Hcl | 40 | $1,477 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSimponi | $19,866 | $74,91713 claims |
| Lilly USA, LLCForteo | $20 | $54,20713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Voorhees
- Joshua SundharVoorhees$137K
- James DwyerVoorhees$35K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.